Global Glycobiology Market Expected to be Valued US$ 1,670.3 Mn by 2024

| December 8, 2016

article image
The term ‘Glycobiology’ was first introduced by Rademacher et al., in 1988, incorporating a varied array of molecules, collectively termed as ‘glycoconjugates’. Glycobiology is a branch of ‘Glycosciences’. Glycoscience is interdisciplinary stream having two branches viz. glycochemistry and glycobiology, which require the involvement of researchers in various disciplines including but not limited to medical science, pharmaceutical science, microbiology, biochemistry, material science, and biotechnology. Extensive research related to carbohydrate molecule in various fields such as marine science and food & beverages industry is expected to fuel growth of the global glycobiology market. The global market is expected to reach a value of US$ 1,670.3 Mn by 2024, registering a CAGR of 12.8% between 2016 and 2024, according to a new report by Persistence Market Research (PMR).

Spotlight

Parkway Pantai Limited

Parkway Pantai Limited (PPL), one of Asia’s largest integrated private healthcare providers operating in Singapore, Malaysia, India, China, Brunei and United Arab Emirates. We employ more than 19,000 staff and operate more than 6000 licensed beds across 28 hospitals in 6 countries worldwide, offering the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services including medical education.

OTHER ARTICLES

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Global Antiviral Drugs Market Growth: Is Antiviral Drug the Best Coronavirus Treatment?

Article | April 9, 2020

The global antiviral drugs market has witnessed a rapid surge in demand due to the ongoing Covid-19 pandemic worldwide. So is antiviral drug the best coronavirus treatment? It is still too early to have that conclusion as many medical research and clinical trials are still trying to find the effectiveness and potential side effects of using antiviral drugs to treat coronavirus. But experts believe that antiviral drug might be the best hope for reduce the coronavirus transmission around the world at this stage. However, due to the current difficult situation of the supply chain in many lockdown countries and regions, there is a global shortage on the antiviral drugs supply. With researchers and manufacturers working hard to find and provide effective coronavirus treatment, it is expected that the global antiviral drugs market will have a significant growth over the near future. Antiviral drugs are a type of medication used specifically for treating viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza.

Read More

Spotlight

Parkway Pantai Limited

Parkway Pantai Limited (PPL), one of Asia’s largest integrated private healthcare providers operating in Singapore, Malaysia, India, China, Brunei and United Arab Emirates. We employ more than 19,000 staff and operate more than 6000 licensed beds across 28 hospitals in 6 countries worldwide, offering the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services including medical education.

Events